Pan-cancer circulating tumor DNA detection in over 10,000 Chinese patients
Circulating tumor DNA (ctDNA) provides a noninvasive approach to elucidate a patient's genomic landscape and actionable information. Here, we design a ctDNA-based study of over 10,000 pan-cancer Chinese patients. Using parallel sequencing between plasma and white blood cells, 14% of plasma cell-free DNA samples contain clonal hematopoiesis (CH) variants, for which detectability increases with age. After eliminating CH variants, ctDNA is detected in 73.5% of plasma samples, with small cell lung cancer (91.1%) and prostate cancer (87.9%) showing the highest detectability. The landscape of putative driver genes revealed by ctDNA profiling is similar to that in a tissue-based database (R2 = 0.87, p < 0.001) but also shows some discrepancies, such as higher EGFR (44.8% versus 25.2%) and lower KRAS (6.8% versus 27.2%) frequencies in non-small cell lung cancer, and a higher TP53 frequency in hepatocellular carcinoma (53.1% versus 28.6%). Up to 41.2% of plasma samples harbor drug-sensitive alterations. These findings may be helpful for identifying therapeutic targets and combined treatment strategies.
| Errataetall: |
ErratumIn: Nat Commun. 2021 Feb 10;12(1):1048. - PMID 33568659 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:12 |
|---|---|
| Enthalten in: |
Nature communications - 12(2021), 1 vom: 04. Jan., Seite 11 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Zhang, Yongliang [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Circulating Tumor DNA |
|---|
| Anmerkungen: |
Date Completed 13.01.2021 Date Revised 07.12.2022 published: Electronic ErratumIn: Nat Commun. 2021 Feb 10;12(1):1048. - PMID 33568659 Citation Status MEDLINE |
|---|
| doi: |
10.1038/s41467-020-20162-8 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM319618145 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM319618145 | ||
| 003 | DE-627 | ||
| 005 | 20231225171831.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1038/s41467-020-20162-8 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1065.xml |
| 035 | |a (DE-627)NLM319618145 | ||
| 035 | |a (NLM)33397889 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Zhang, Yongliang |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Pan-cancer circulating tumor DNA detection in over 10,000 Chinese patients |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 13.01.2021 | ||
| 500 | |a Date Revised 07.12.2022 | ||
| 500 | |a published: Electronic | ||
| 500 | |a ErratumIn: Nat Commun. 2021 Feb 10;12(1):1048. - PMID 33568659 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Circulating tumor DNA (ctDNA) provides a noninvasive approach to elucidate a patient's genomic landscape and actionable information. Here, we design a ctDNA-based study of over 10,000 pan-cancer Chinese patients. Using parallel sequencing between plasma and white blood cells, 14% of plasma cell-free DNA samples contain clonal hematopoiesis (CH) variants, for which detectability increases with age. After eliminating CH variants, ctDNA is detected in 73.5% of plasma samples, with small cell lung cancer (91.1%) and prostate cancer (87.9%) showing the highest detectability. The landscape of putative driver genes revealed by ctDNA profiling is similar to that in a tissue-based database (R2 = 0.87, p < 0.001) but also shows some discrepancies, such as higher EGFR (44.8% versus 25.2%) and lower KRAS (6.8% versus 27.2%) frequencies in non-small cell lung cancer, and a higher TP53 frequency in hepatocellular carcinoma (53.1% versus 28.6%). Up to 41.2% of plasma samples harbor drug-sensitive alterations. These findings may be helpful for identifying therapeutic targets and combined treatment strategies | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a Circulating Tumor DNA |2 NLM | |
| 700 | 1 | |a Yao, Yu |e verfasserin |4 aut | |
| 700 | 1 | |a Xu, Yaping |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Lifeng |e verfasserin |4 aut | |
| 700 | 1 | |a Gong, Yan |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Kai |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Meng |e verfasserin |4 aut | |
| 700 | 1 | |a Guan, Yanfang |e verfasserin |4 aut | |
| 700 | 1 | |a Chang, Lianpeng |e verfasserin |4 aut | |
| 700 | 1 | |a Xia, Xuefeng |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Lin |e verfasserin |4 aut | |
| 700 | 1 | |a Jia, Shuqin |e verfasserin |4 aut | |
| 700 | 1 | |a Zeng, Qiang |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Nature communications |d 2010 |g 12(2021), 1 vom: 04. Jan., Seite 11 |w (DE-627)NLM199274525 |x 2041-1723 |7 nnns |
| 773 | 1 | 8 | |g volume:12 |g year:2021 |g number:1 |g day:04 |g month:01 |g pages:11 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1038/s41467-020-20162-8 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 12 |j 2021 |e 1 |b 04 |c 01 |h 11 | ||